Immatics (NASDAQ:IMTXW – Get Free Report) shares traded down 0.7% on Monday . The stock traded as low as $0.19 and last traded at $0.19. 2,133 shares changed hands during trading, a decline of 87% from the average session volume of 15,892 shares. The stock had previously closed at $0.19.
Immatics Price Performance
The business’s fifty day moving average price is $0.70 and its 200-day moving average price is $2.05.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Read More
- Five stocks we like better than Immatics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Why Are These Companies Considered Blue Chips?
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
